Enzymatic Therapy's(R) Vitaline(R) Smart Q10(TM) Proven to be Safe and Well Tolerated

GREEN BAY, Wis., Feb 02, 2006 (BUSINESS WIRE) -- Today Enzymatic Therapy, Inc. (ETI), a leading manufacturer and distributor of nutritional supplements, announced positive safety and tolerability results from the most recent neurological study using its Vitaline SmartQ10 supplement. (1) Impressive clinical study results, quality manufacturing and a formula now containing natural Vitamin E, have caused this supplement to become a hit in medical circles that have not been very conducive to nonprescription alternatives in the past.

The recent study assessed the safety and tolerability of high doses of Vitaline SmartQ10 for support of neurological health.(a) Published in the December 13th, issue of Neurology journal, the researchers selected Vitaline Smart Q10 because it has been determined to cross the blood-brain barrier, has been used in prior neurological research, has the highest level of purity, and has a specialized delivery system to assure absorption. The chewable form was particularly advantageous because it was easier to swallow, which is important in individuals with impaired swallowing ability. The researchers found that Vitaline Smart Q10 was very safe and well tolerated in this sensitive population. Now that the safety and tolerability have been demonstrated in this community, plans are underway for a larger study using the supplement.

This is the 26th clinical study to use Vitaline Smart Q10 and there are 19 others underway. Because it's made in ETI's FDA registered drug manufacturing facility, the product has high quality and consistency, and has become the supplement of choice for clinical studies.

Vitaline Smart Q10 comes in varying strengths that range from 60 mg to 200 milligrams. It's one of many best-selling products in the over 200 dietary supplements manufactured and distributed by Enzymatic Therapy, Inc. Available at retail outlets nationwide, go to www.enzy.com for more information on Vitaline Smart Q10.

(1)Ferrante KL, Shefner J, Zhang H, et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS (Amyotrophic Lateral Sclerosis also known as Lou Gehrig's Disease). Neurology. 2005;65:1834-1836.

(a)This statement has not been evaluated by the food and drug administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.